Using prostate‐specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer
- 8 June 2006
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 98 (1) , 11-19
Abstract
In this section there are two reviews concerning prostate cancer, both from the same group of authors. In the first, they describe the combination of nomograms with PSA screening to assess risk and to predict outcomes in the management of prostate cancer. In the second, they indicate how outcomes and quality of life can be optimised in the hormonal treatment of prostate cancer. Botulinum toxin has become very popular in the management of a whole range of conditions both inside and outside the urinary tract. Now it has been extended to prostatic disorders, and the mini‐review presented here has evaluated reports and the authors’ personal experience in the mechanisms of action and clinical efficacy of Botulinum toxin in the prostate. Finally, there is a mini‐review of FISH in bladder cancer, particularly its development, applications, and its potential for the future. We review the role of prostate‐specific antigen (PSA) and the importance of patient education in the management of prostate cancer, based on discussions held at a European symposium on managing prostate cancer. Although PSA is the most widely used serum marker for detecting prostate cancer and for monitoring treatment responses, its use as a diagnostic marker is controversial due to concerns of over‐diagnosis and low specificity. PSA isoforms, as well as PSA doubling time, might improve the specificity for earlier prostate cancer detection and can be used as surrogate markers for treatment efficacy. Patients can differ considerably in the importance they place on health‐related quality of life aspects and fear of cancer progression. Consequently, there needs to be active, educated discussion of risk and outcomes between physicians and patients. Risk assessment tools, e.g. validated nomograms, enable clinicians to improve their decision analysis and form the basis for subsequent discussion of treatment options between the physician and patient, thereby enabling informed consent and appropriate decision‐making.Keywords
This publication has 85 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- 4-YEAR PROSTATE SPECIFIC ANTIGEN PROGRESSION AND DIAGNOSIS OF PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAMJournal of Urology, 2005
- Radical Prostatectomy versus Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2005
- PSA Updated: Still Relevant in the New Millennium?European Urology, 2005
- DEFINITIONS OF BIOCHEMICAL FAILURE THAT BEST PREDICT CLINICAL FAILURE IN PATIENTS WITH PROSTATE CANCER TREATED WITH EXTERNAL BEAM RADIATION ALONE: A MULTI-INSTITUTIONAL POOLED ANALYSISJournal of Urology, 2005
- Radical Prostatectomy Nomograms in Black American Men: Accuracy and ApplicabilityJournal of Urology, 2003
- Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence After Radical Prostatectomy for Localized Prostate CancerJournal of Clinical Oncology, 2002
- Serum Markers as a Predictor of Response Duration and Patient Survival After Hormonal Therapy for Metastatic Carcinoma of the ProstateJournal of Urology, 1997
- The impact of informed consent on patient interest in prostate-specific antigen screeningArchives of internal medicine (1960), 1996
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993